<a href="https://laohu8.com/S/ASND">Ascendis Pharma A/S</a> Secures Australian Regulatory Approval for SKYTROFA®, a New Once-Weekly Therapy for Paediatric Growth Hormone Deficiency
Ascendis Pharma A/S has announced the Australian registration of SKYTROFA® (lonapegsomatropin) by the Therapeutic Goods Administration $(TGA)$ as a once-weekly injectable therapy for paediatric growth hormone deficiency. This approval is a significant milestone for Ascendis Pharma and its distribution partner, Specialised Therapeutics $(ST)$, marking the second endocrinology therapy registered in Australia by ST. SKYTROFA is designed to treat growth failure in children and adolescents aged 3 to 18 due to insufficient endogenous growth hormone secretion, aiming to improve not only stature but also address the physical and psychosocial impacts associated with the condition. This approval follows prior endorsements by the US FDA and the European Medicines Agency.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via PR Newswire (Ref. ID: CN98546) on May 29, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。